- ICH GCP
- Registr klinických hodnocení EU
Poslední zkoušky
EudraCT Number: 2022-002378-95 | Sponsor Protocol Number: D7000C00001 | Start Date: 2023-06-21 | |||||||||||
Sponsor Name: AstraZeneca AB | |||||||||||||
Full Title: A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions ... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) DK (Ongoing) DE (Ongoing) ES (Ongoing) SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000692-39 | Sponsor Protocol Number: IVY | Start Date: 2023-06-19 | |||||||||||
Sponsor Name: Amsterdam University Medical Center | |||||||||||||
Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva | |||||||||||||
Medical condition: Fibrodyplasia Ossificans Progressiva (FOP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002718-17 | Sponsor Protocol Number: IMVT-1401-2401 | Start Date: 2023-06-19 | |||||||||||
Sponsor Name: Immunovant Sciences, GmbH | |||||||||||||
Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NO (Ongoing) FI (Ongoing) SE (Ongoing) DK (Ongoing) SK (Ongoing) BG (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003594-33 | Sponsor Protocol Number: EORTC-1984-BCG | Start Date: 2023-06-16 | |||||||||||
Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE) | |||||||||||||
Medical condition: Triple negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002234-14 | Sponsor Protocol Number: OR2805-101 | Start Date: 2023-06-07 | ||||||
Sponsor Name: OncoResponse, Inc. | ||||||||
Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies | ||||||||
Medical condition: Solid tumor cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: ES (Ongoing) FR (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003467-21 | Sponsor Protocol Number: AROMUC5AC-1001 | Start Date: 2023-06-07 | |||||||||||
Sponsor Name: Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001403-33 | Sponsor Protocol Number: TCTLR-101 | Start Date: 2023-06-06 | ||||||||||||||||||||||||||
Sponsor Name: Ascendis Pharma Oncology Division A/S | ||||||||||||||||||||||||||||
Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor... | ||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumor malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002313-41 | Sponsor Protocol Number: CRC2021-02 | Start Date: 2023-06-06 | ||||||||||||||||
Sponsor Name: CENTRO RICERCHE CLINICHE DI VERONA | ||||||||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S... | ||||||||||||||||||
Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000690-73 | Sponsor Protocol Number: BAY86-5321/21912 | Start Date: 2023-06-06 | |||||||||||
Sponsor Name: Bayer AG | |||||||||||||
Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi... | |||||||||||||
Medical condition: Neovascular (wet) age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000054-28 | Sponsor Protocol Number: OLIGOTREAT | Start Date: 2023-06-02 | |||||||||||
Sponsor Name: Klinikum der Universität München | |||||||||||||
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |